Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
CBUS
Strong SellSinkerCibus, Inc. · Healthcare · United States · $126M · Avg Vol: $208K/d
COMPANY DESCRIPTION
Cibus, Inc. develops and commercializes advanced non-GMO and gene-edited plant traits for agricultural applications, focusing on improving crop yields and sustainability. The company leverages its proprietary Rapid Trait Development System (RTDS) platform, allowing precise genetic modifications without introducing foreign DNA. Cibus is a pioneer in sustainable agricultural biotechnology, offering an alternative to traditional GMOs.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 26.0M | 0.2M | 1.8M | 4.3M | 3.6M | -38.8% | 4.3M | 5.2M | — | 42.8% |
| EPS | -39.00 | -0.24 | -6.99 | -3.96 | -2.78 | — | -1.51 | -0.77 | -0.64 | — |
| Shares | 0.8M | 76.3M | 76.3M | 76.3M | 54.3M | +6887.4% | — | — | — | — |
| Debt | 17.9M | 13.9M | 24.6M | 36.3M | 33.0M | 16.6% | 286.3M | — | — | — |
| Equity | 14.1M | 7.2M | 293.5M | 92.2M | 21.8M | 11.5% | — | — | — | — |
| Op CF | -18.8M | -19.4M | -46.2M | -58.0M | -50.6M | — | -46.1M | — | — | — |
| Inv CF | 11.2M | -1.5M | 55.1M | -0.8M | -0.6M | — | — | — | — | — |
| Fin CF | 3.7M | 10.0M | 20.3M | 40.6M | 46.6M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CBUS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| CBUS | Cibus, Inc.(you) | $126M | 2 | Strong Sell |
| INO | Inovio Pharmaceuticals, Inc. | $133M | 3 | Strong Sell |
| NTHI | NeOnc Technologies Holdings, Inc. | $122M | 0 | Strong Sell |
| 2592.HK | Cloudbreak Pharma Inc. | $136M | 1 | Strong Sell |
| GNLX | Genelux Corporation | $120M | 4 | Strong Sell |
| NAUT | Nautilus Biotechnology, Inc. | $113M | 4 | Strong Sell |
| HURA | TuHURA Biosciences, Inc. | $134M | 6 | Strong Sell |
| ONCY | Oncolytics Biotech Inc. | $109M | 5 | Strong Sell |
| RANI | Rani Therapeutics Holdings, Inc. | $118M | 7 | Strong Sell |
| PLYX | Polaryx Therapeutics, Inc. | $103M | 5 | Strong Sell |
Peer medians: ROE -30.2% · P/E 27.0x · Gross margin 58.1%